indicated and validated the enrichment of innate-like CD161+CD8+ T cells with limited cytotoxic ability in relapsed HCC tissues and may have poor response to the subclonal neoantigens in early-relapsed tumor cells, providing new targets to restrain HCC relapse (80). The gene discussed is CD8A; the disease is hepatocellular carcinoma.